ArticleCardiovascular diabetology2026

Henagliflozin attenuates adverse ventricular remodeling and improves cardiometabolic parameters in patients with type 2 diabetes and hypertension: real-world evidence from a propensity score-matched analysis.

Nianfang Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.